Parties and Attorneys
Asahi Kasei Pharma Corporation v. Actelion Ltd. et al.
Division 5
Division 5
Case Number A133927
| Party | Attorney |
|---|---|
| Asahi Kasei Pharma Corporation : Plaintiff and Appellant | Christopher John Banks Morgan Lewis & Bockius 1 Market Street - Spear Street Tower San Francisco, CA 94105 Thomas Marven Peterson Morgan Lewis & Bockius 1 Market Street - Spear Street Tower San Francisco, CA 94105 |
| Actelion Ltd. : Defendant and Appellant | Donald Manwell Falk Mayer Brown 2 Palo Alto Square - Suite 300 3000 El Camino Real Palo Alto, CA 94306-2112 Nanci Eiko Nishimura Cotchett, Pitre & McCarthy 840 Malcolm Road - Suite 200 Burlingame, CA 94010 Evan M. Tager Mayer Brown LLP 1999 K Street, NW Washington, DC 20016-1101 |
| Actelion Pharmaceuticals Ltd. : Defendant and Appellant | |
| Actelion Pharmaceuticals US Inc. : Defendant and Appellant | |
| Actelion US Holding Company : Defendant and Appellant | |
| Jean-Paul Clozel : Defendant and Appellant | Susan Heikkinen Handelman Ropers, Majeski, Kohn & Bentley 1001 Marshall Street - Suite 500 Redwood City, CA 94063-2052 Kathleen Marie Sullivan Quinn Emanuel et al LLP 555 Twin Dolphin Dr #560 Redwood Shores, CA 94065 Daniel Bromberg Quinn Emanuel Urquhart & Sullivan, LLP 555 Twin Dolphin Drive, 5th Floor Redwood Shores, CA 94065 |
| Martine Clozel : Defendant and Appellant | |
| Simon Buckingham : Defendant and Appellant | |
| Medivation, Inc. : Information only | James Kevin Lynch Latham & Watkins 505 Montgomery Street - Suite 2000 San Francisco, CA 94111 |
Case Summary
Trial Court Case:
CIV478533
Court of Appeal Case:
A133927
Supreme Court Case:
S216123
Division:
5
Case Caption:
Asahi Kasei Pharma Corporation v. Actelion Ltd. et al.
Case Type:
CV
Filing Date:
12/02/2011
Completion Date:
03/14/2014
Oral Argument Date/Time:
11/21/2013 09:00 AM
Docket (Register of Actions)
Asahi Kasei Pharma Corporation v. Actelion Ltd. et al.
Division 5
Division 5
Case Number A133927
| Date | Description | Notes |
|---|---|---|
| 12/06/2011 | Notice of appeal lodged/received. | by attorney Donald M. Falk (Mayer Brown) for Actelion Ltd. et al. (defendant); notice of appeal filed in the superior court on 12/02/2011 |
| 12/06/2011 | Notified parties of local rules and procedures. | |
| 12/06/2011 | Filing fee. | as to Actelion Ltd. et al. appeal; from A & A Legal Service Inc. [1541 Bayshore Highway; Burlingame, CA 94010; (650) 697-9431]; check number 2590 issued 12/02/2011 |
| 12/06/2011 | Notice of appeal lodged/received. | by attorney Susan H. Handelman (Ropers Majeski Kohn & Bently) for Jean-Paul Clozel et al. (defendants); notice of appeal filed in the superior court on 12/02/2011 |
| 12/06/2011 | Filing fee. | as to Jean-Paul Clozel et al. appeal; from Ropers Majeski Kohn & Bently; check number 188531 issued 11/30/2011 |
| 12/16/2011 | Notice of appeal lodged/received. | by attorney Benjamin P. Smith (Morgan Lewis & Bockius) for Asahi Kasei Pharma Corporation (plaintiff); notice of cross-appeal filed in the superior court on 12/12/2011 |
| 12/16/2011 | Filing fee. | as to Asahi Kasei Pharma Corporation cross appeal; from Specialized Legal Services [P. O. Box 77141; San Francisco, CA 94107; (415) 357-0500]; check number 40868 issued 12/12/2011 |
| 12/16/2011 | Notified parties of local rules and procedures. | as to Asahi Kasei Pharma Corporation cross appeal |
| 12/16/2011 | Notice per rule 8.124 - with reporter's transcript. | as to Actelion Ltd. et al. appeal; notice filed in the superior court on 12/13/2011 |
| 12/16/2011 | Notice per rule 8.124 - with reporter's transcript. | as to Jean-Paul Clozel et al. appeal; notice filed in the superior court on 12/13/2011 |
| 12/16/2011 | Certificate of interested entities or persons filed by: | attorney Donald Falk for appellant Actelion Ltd. |
| 12/16/2011 | Certificate of interested entities or persons filed by: | attorney Susan Handelman for appellants Jean-Paul Clozel et al. |
| 12/16/2011 | Civil case information statement filed. | as to Actelion Ltd. et al. appealby attorney Donald Falk for appellant (Actelion Ltd., et al.,) w/a copy of the amended judgment attached. |
| 12/16/2011 | Civil case information statement filed. | as to Jean-Paul Clozel et al. appealby attorney Susan Handelman for appellants (J.P. Clozel, M. Clozel and S. Buckingham). A copy of the judgment is needed. |
| 12/20/2011 | Filed document entitled: | An amended CCIS faxed from attorney Susan Handelman w/a copy of the amended judgment attached. |
| 12/27/2011 | Received default notice 8.121(a) designation not filed. Dated: | as to Asahi Kasei Pharma Corporation cross appeal ; default notice issued by the superior court on 12/23/2011 |
| 12/23/2011 | Certificate of interested entities or persons filed by: | attorney Sharon Smith for respondent Asahi Kasie Pharma Corp. |
| 12/27/2011 | Received document entitled: | respondent's (Asahi Kasei Pharma Corporation cross appeal) notice designating additional reporter transcripts; notice filed in the superior court on 12/23/2011 |
| 12/23/2011 | Civil case information statement filed. | as to Asahi Kasei Pharma Corporation cross appealby attorney Franklin Gowdy for appellant (Asahi Kasei Pharma Corp.,) w/a copy of the judgment attached. |
| 12/29/2011 | Notice to reporter to prepare transcript. | sent to CSR's Annette Jaycox, rhonda Guess, Lorna Traube & Megan Zalmai dated 12/23/11. Txs due 2/21/11. |
| 01/03/2012 | Received: | Stipulated proposed briefing sequence from attorney Susan Handelman for Jean-Paul Clozel etc. ***Need original signatures on all pages*** |
| 01/06/2012 | Proposed briefing sequence filed by: | Stipulated Proposed Briefing Sequence |
| 01/06/2012 | Notice to reporter to prepare transcript. | sent to CSR's Annette Jaycox, Rhonda Guess, Lorna Traube and Megan Zalmai dated 1/5/12. Txs due 3/5/12. |
| 01/10/2012 | Received document entitled: | Asahi Kasei Pharma Corporation notice designating record as to their cross appeal; notice filed in the superior court on 01/06/2012 |
| 01/10/2012 | Briefing sequence order filed. | The parties' "Stipulated Proposed Briefing Sequence," filed on January 5, 2011, is granted as follows: Appellants Actelion Ltd. et al.'s (Actelion Entities) opening brief shall be due 40 days from the filing of the record on appeal. Appellants Jean-Paul Clozel et al.'s (Individuals) opening brief shall also be due 40 days from the filing of the record on appeal. The combined respondent's/opening brief by Asahi Kasei Pharma Corporation (Asahi) shall be due 30 days from the filing of the last opening brief. The combined reply/respondents' brief by Actelion Entities shall be due 30 days from the filing of the Asahi brief. The combined reply/respondents' brief by Individuals shall also be due 30 days from the filing of the Asahi brief. Respondent Asahi may file a reply brief on cross-appeal issues only within 20 days of the filing of the last combined brief. |
| 01/17/2012 | Received document entitled: | "Appeal Bond/Undertaking-Defendants' Joint and Several Liability" filed in the Superior Court. |
| 01/26/2012 | Received document entitled: | "Rider to Appeal Bond No. 015035914 on Behalf of Jean-Paul Clozel" filed in Superior Court |
| 02/23/2012 | Court reporter extension requested. | by CSR Megan Zalmai to 4/21/12. |
| 03/01/2012 | Court reporter extension granted. | CSR: Zalmai, Megan E (10925) Extended Due Date: 04/19/2012 |
| 04/25/2012 | Court reporter extension requested. | by CSR Megan Zalmai to 5/21/12. |
| 05/01/2012 | Court reporter extension granted. | CSR: Zalmai, Megan E (10925) Extended Due Date: 05/21/2012 |
| 06/11/2012 | Notice of record completion received. | |
| 06/11/2012 | Record on appeal filed. | r-89 (rule 8.124) |
| 06/11/2012 | Record in box. | five (5) boxes |
| 07/02/2012 | Pro hac vice application | Application of Evan M. Tager on behalf of appellants Actelion Ltd. et al. |
| 07/10/2012 | Pro hac vice granted | Appellants Actelion Ltd. et al., having filed an application on July 2, 2012, on behalf of Mr. Evan M. Tager, of Mayer Brown LLP, 1999 K Street, N.W., Washington, D.C. 20006, to be admitted as counsel pro hac vice and having met the requirements of California Rules of Court, rule 9.40, said application is granted. Mr. Tager is hereby permitted to appear as counsel pro hac vice for appellants Actelion Ltd. et al. |
| 07/23/2012 | Appellant's opening brief. | Defendant and Appellant: Jean-Paul Clozel Attorney: Susan Heikkinen Handelman Defendant and Appellant: Martine Clozel Defendant and Appellant: Simon Buckingham |
| 07/23/2012 | Application filed to: | Appellants Clozel et. al.'s (Individual) application for leave to file a redacted and unredacted public versions of appellants' appendix |
| 07/23/2012 | Appellant's appendix filed. | 14 boxes of appendices containing SEALED and UNSEALED versions filed by appellants Jean-Paul Clozel et al. ***filing granted per order on 8/15/12***2 CD included (Redacted and Unredacted Versions)by Jean-Paul Clozel, Defendant and Appellant Susan Handelman, Retained counsel |
| 07/24/2012 | Application filed to: | for leave to file oversized (18,996 words) brief by appellants Actellion et al. (Actellion Entities); brief attached |
| 07/24/2012 | Application filed to: | Appellants Actellion Entities application for leave to file AOB under seal and a redacted public version; brief attached |
| 07/24/2012 | Appellant's opening brief. | Defendant and Appellant: Actelion Ltd. Attorney: Donald Manwell Falk Defendant and Appellant: Actelion Pharmaceuticals Ltd. Defendant and Appellant: Actelion Pharmaceuticals US Inc. Defendant and Appellant: Actelion US Holding Company 07/23/2012REDACTED AND UNREDACTED versions per order filed on 8/15/12 |
| 08/15/2012 | Order on motion filed. | Appellants Jean-Paul Clozel et al.'s "application for leave to file redacted and unredacted versions of appellants' appendices," filed on July 23, 2012, is granted. (See Cal. Rules of Court, rule 8.46(c).) Appellants Actelion Ltd. et al.'s applications for leave to file: (1) an oversized opening brief; and (2) redacted and unredacted versions of opening brief, filed on July 24, 2012, are granted. (See Cal. Rules of Court, rules 8.204(c)(5), 8.46(e).) The clerk of this court is directed to file the redacted and unredacted versions of appellants' opening brief and appendices forthwith. The unredacted version must be filed under seal and must be removed from the public record on appeal, and they may not be reviewed without an order from this court. (See Cal. Rules of Court, rule 8.46(f).) |
| 08/20/2012 | Stipulation of extension of time filed to: | Respondent's brief. Due on 10/02/2012 By 40 Day(s) |
| 09/24/2012 | Stipulation of extension of time filed to: | Respondent's brief. Due on 10/22/2012 By 20 Day(s) |
| 10/17/2012 | Requested - extension of time. | Respondent's brief. Requested for 11/13/2012 By 22 Day(s) |
| 10/23/2012 | Granted - extension of time. | Respondent's brief. Due on 11/13/2012 By 22 Day(s) |
| 11/19/2012 | Respondent notified re failure to file respondent's brief. | Plaintiff and Appellant: Asahi Kasei Pharma Corporation Attorney: Christopher John Banks |
| 12/04/2012 | Application filed to: | Respondent/Cross-appellant Asahi Kahei Pharma Corporations's Unopposed Application for leave to file oversized brief; brief attached |
| 12/04/2012 | Application filed to: | Respondent and Cross-appellant Asahi Kasei Pharma Corporation's application to file brief under seal and public version 7 volumes of appendices (SEALED) 7 volumes of appendices (PUBLIC) |
| 12/26/2012 | Order filed. | Respondent Asahi Kasei Pharma Corporation's "application to file a combined brief and appendix under seal and redacted public version" filed on December 4, 2012, is granted. (Cal. Rules of Court, rule 8.46(c).) Respondent's application to file a combined brief in excess of the 28,000 word limit as set forth in California Rules of Court, rule 8.204(c)(4), is denied. Respondent may file a combined brief and appendix in full compliance with the California Rules of Court within fifteen (15) days of the date of this order. |
| 01/11/2013 | Respondent's brief. | Plaintiff and Appellant: Asahi Kasei Pharma Corporation Attorney: Christopher John Banks 11/13/2012***Redacted and unredacted versions; see order filed on 12/26/12*** 2 CDs containing the redacted and unredacted briefs |
| 01/10/2013 | Respondent's appendix filed. | 7 volumes of redacted and unredacted versions. See order filed on 12/26/12 |
| 01/10/2013 | Record in box. | 2 boxes containing respondent's brief and appendices (redacted and unredacted) |
| 02/06/2013 | Stipulation of extension of time filed to: | Appellant's reply brief. Due on 03/13/2013 By 30 Day(s) ***for both appellants*** |
| 03/13/2013 | Application filed to: | Appellants Actellion Ltd. et al.'s application to file redacted and unredacted ARB/X-RB; SEALED and UNSEALED briefs are attached |
| 03/13/2013 | Application filed to: | Appellants Jean-Paul Clozel et al.'s application to file a redacted and unredacted versions of "supplemental appendix" 1 volume of SEALED and UNSEALED versions are attached |
| 04/05/2013 | Order filed. | Appellants Actelion Ltd. et al.'s "application for leave to file a redacted and unredacted versions of their reply and cross-respondents' brief," filed on March 13, 2013, is granted. (Cal. Rules of Court, rule 8.46(c).) Appellants Jean-Paul Clozel et al.'s "application to file a redacted and unredacted versions of appellants' supplemental appendix," filed on March 13, 2013, is also granted. (Cal. Rules of Court, rule 8.46(c).) The clerk of this court is directed to file the redacted and unredacted versions of appellants' reply and cross-respondents' brief and supplemental appendix forthwith. The unredacted version must be filed under seal and must be removed from the public record on appeal, and it may not be reviewed without an order from this court. (See Cal. Rules of Court, rule 8.46(f).) |
| 04/05/2013 | Appellant's reply brief. | Defendant and Appellant: Actelion Ltd. Attorney: Donald Manwell Falk 03/13/2013***redacted and unrdacted versions**** |
| 04/05/2013 | Appellant's reply brief. | Defendant and Appellant: Jean-Paul Clozel Attorney: Susan Heikkinen Handelman 03/13/20131 volume of public version of appendix 1 volume of SEALED appendix 2 CDs containing the public and SEALED versions of appendix (in gray envelope) |
| 03/25/2013 | Stipulation of extension of time filed to: | Appellant's reply brief. Due on 05/02/2013 By 7 Day(s) |
| 05/03/2013 | Appellant's reply brief. | Plaintiff and Appellant: Asahi Kasei Pharma Corporation Attorney: Christopher John Banks X-ARBfiled per AR 8.25(b)(3) |
| 05/03/2013 | Case fully briefed. | |
| 05/31/2013 | Oral argument waiver notice sent. | |
| 06/02/2013 | Record to court for review. | |
| 06/05/2013 | Request for oral argument filed by: | Evan M. Tager for appellant |
| 06/05/2013 | Request for oral argument filed by: | Susan M. Hendelman for appellant Jean-Paul Clozel et al. |
| 06/07/2013 | Request for oral argument filed by: | Thomas Peterson for respondent Asahi Kasei Pharma |
| 08/26/2013 | Received letter from: | Attorney Evan Tager for appellants re unavailability for oral argument from October 15 to Novemeber 13, 2013; missing proof of service |
| 09/05/2013 | Received letter from: | Attorney Evan Tager re new citation; missing proof of service |
| 09/06/2013 | Filed additional cites for oral argument. | from attorney Evan Tager for appellants Actellion et al. re new citation |
| 10/15/2013 | Calendar notice sent. Calendar date: | November 21, 2013 at 9:00 a.m. |
| 10/30/2013 | Change of contact information filed for: | Evan M. Tager old address 1: 5135 52nd Street, N.W. new address 1: 1999 K Street, NW old zip ext: {blank} new zip ext: 1101 old phone: (650) 331-2000 new phone: (202) 263-3000 old fax: (650) 331-2061 new fax: (202) 263-3300 |
| 11/12/2013 | Application filed to: | Application for Leave to Use Laptop Computer at Counsel Table During OA from attorney Donald Falk for appellants |
| 11/14/2013 | Order filed. | BY THE COURT: Appellants' "Application for Leave to Use Laptop Computer at Counsel Table During Oral Argument," filed herein on November 12, 2013, is granted. |
| 11/15/2013 | Filed additional cites for oral argument. | by Actellion Ltd. et al. |
| 11/19/2013 | Letter sent to counsel re: | To all counsel: Oral argument is currently scheduled in this matter on November 21, 2013, at 9:00 a.m. Each side will be allocated a total of 20 minutes for argument. The Actelion entities and the individual defendants will be considered one side for purposes of argument on all issues, and are directed to meet and confer to allocate time between them and to avoid unnecessary duplication of argument. |
| 11/21/2013 | Cause argued and submitted. | |
| 11/25/2013 | Filed letter from: | respondent Asahi Kasie Pharma requesting a copy of oral argument held on 11/21/13; $20 check attached |
| 11/26/2013 | Filed letter from: | Actellion, Ltd. asking for a copy of the oral argument; $20 check attached |
| 12/03/2013 | Note: | sent copies of oral argument to Asahi Kasei Pharma and Actellion et al. per requests. |
| 12/05/2013 | Received letter from: | attorney Rollin Chippey for respondent Asahi Kasei Pharma re new citation published by the Second Appellate District; missing proof of service |
| 12/12/2013 | Received letter from: | Rachele M. Bohnet, assistant to Rollin B. Chippey II re letter and additional citation received on 12/5/13; proof of service is attached. |
| 12/16/2013 | Received letter from: | Katherine McGrath (third party) asking for a copy of the oral argument; $20 check attached |
| 12/18/2013 | Opinion filed. | (Signed Partial Published) The judgments are affirmed. Asahi shall recover its costs on appeal. |
| 01/02/2014 | Rehearing petition filed. | Actelion et al. |
| 01/02/2014 | Rehearing petition filed. | Clozel et al. |
| 01/07/2014 | Filed request to publish opinion. | by attorney James Lynch of Latham Watkin for Third Party Medivation, Inc. |
| 01/14/2014 | Received: | Asah Kasei's opposition to the request for publication by Medivation |
| 01/16/2014 | Mod. of opinion filed (no change in judgment). | The opinion in the above-entitled matter filed on December 18, 2013, was certified for publication with the exception of parts II.B., II.C., II.D., and II.E. On January 7, 2014, a nonparty request for full publication was filed pursuant to California Rules of Court, rule 8.1120(a). Pursuant to California Rules of Court, rules 8.1105(b)(2), (b)(4), (c), and 8.1110, and for good cause appearing, this court grants that request in part and orders the opinion certified for publication with the exception of parts II.B., II.C.3., II.C.4., II.D., and II.E. IT IS FURTHER ORDERED that the opinion filed on December 18, 2013, is modified as follows and the petitions for rehearing are DENIED: 1. On page 5, in part I, the first sentence and first clause of the second sentence of the second full paragraph are amended to read: Actelion had been following Ventavis since 2002 and had considered acquiring CoTherix to get rights to the drug, but as late as May 29, 2006, considered the company a second-rate opportunity because of Ventavis's shortcomings. Shortly after the June 28, 2006 public announcement of the License Agreement, Martine noted Fasudil's promise and the company began to explore the option of acquiring CoTherix. In July 2006, 2. On page 14, the entire paragraph in part II.A.2. is amended to read: We independently review Defendants' legal challenge to the scope of potential liability for the tort of intentional interference with contract. (Ghirardo v. Antonioli (1994) 8 Cal.4th 791, 800.) 3. On page 49, in the first paragraph of part II.C., the third sentence is amended to read: The jury also awarded Asahi $187.4 million in development costs and $75,000 in investigator-sponsored study costs that CoTherix would have incurred for Asahi's benefit to bring Fasudil to market if it had continued to perform under the contract. 4. On page 49, in part II.C., footnote no. 25 is amended to read: 25 The jury award of $450,000 in IND/Regulatory maintenance costs is not separately challenged here.5. On page 52, in part II.C.2.a., the fourth sentence of the second full paragraph is amended to read: Increases in creatinine levels shown in the IR Fasudil studies were not clinically significant except at high doses. Increases in creatinine levels in ER Fasudil studies were not clinically significant and were reversible. 6. On page 62, in part II.C.3.b., footnote no. 33 is amended to read: 33 This analysis also applies to the award of investigator-sponsored study costs insofar as studies of inhaled Fasudil is concerned. Because Actelion does not attempt to segregate the amount of such costs that were attributable to inhaled Fasudil versus other formulations of Fasudil, it has forfeited any argument that a portion of the award of these costs should have been included in the remittitur. (Guthrey v. State of California (1998) 63 Cal.App.4th 1108, 1115-1116 [appellate court may deny claim on appeal that is unsupported by argument or citations to the record].) 7. On page 63, in part II.C.3.b., footnote no. 34 is deleted (with all following footnotes renumbered accordingly). 8. On page 63, a new final paragraph of part II.C.3.b. is added to read: Actelion further argues that the award was not supported by substantial evidence of proximate causation. However, CoTherix was obligated to pursue development of inhaled Fasudil as long as the License Agreement remained in effect, and the evidence that oral Fasudil was likely to be approved and sold as anticipated supports the inference that, absent interference by the Defendants, the License Agreement would have remained in effect through 2019. 9. On page 64, in part II.C.4., the first sentence of the first full paragraph is amended to read: On the evidence presented at trial, the jury reasonably could have found that-absent Actelion's tortious interference-CoTherix would not have exercised its termination right in 2009 or any time before 2019. 10. On page 67, in part II.D.1., lines 10 through 16 of the first partial paragraph are amended to read: Indeed, several comments attributed to the Individual Defendants themselves are consistent with the comments that Actelion attempts to set apart: Simon's notes of an August 28, 2006 telephone conference could be construed to suggest that Actelion should "mudsling . . . Fasudil['s] great promise," and Simon wrote on the eve of the acquisition that if Asahi balked at the contract termination, "we could discuss risk-benefit ratio and the need to discuss several issues with the FDA before proceeding! I think [we] will be able to deal with them effectively!" Jean Paul personally wrote the March 23, 2007 letter indicating that Actelion might make adverse statements about Fasudil's safety to the FDA and the public if it was unable to resolve its dispute with Asahi and the jury reasonably could have found that this letter was a wrongful threat. And Martine The modification effects no change in the judgment. |
| 01/27/2014 | Association of attorneys filed for: | Kathleen M. Sullivan and Daniel Bromberg of Quinn Emanuel Urquhart for appellants Actelion Ltd, et al. |
| 01/28/2014 | Service copy of petition for review received. | appellants Actelion et al. |
| 02/03/2014 | Record transmitted to Supreme Court. | |
| 02/19/2014 | Received copy of: | answer to Petition for Review |
| 02/21/2014 | Received copy of: | Amicus brief by Pacific Legal Foundation in support of the petition for review |
| 02/26/2014 | Received copy of: | letter dated Feb. 25, 2014 from Durie Tangri |
| 03/04/2014 | Received copy of: | Application of Respondent Asahi Kasei Pharma Corporation to Respond to the Seven Letters in Support of Review |
| 03/04/2014 | Received copy of: | letter dated Feb. 27, 2014 from Washington Legal Foundation |
| 03/05/2014 | Received copy of: | letter from attorney Thomas Peterson for respondent Asahi Kasei Pharma addressed to the Supreme Court in support of the review. |
| 03/13/2014 | Received copy of: | letter from Steven Mayer for Recology in support of the petition for review in the CA Supreme Court |
| 03/14/2014 | Petition for review denied in Supreme Court. | |
| 03/14/2014 | Remittitur issued. | |
| 03/14/2014 | Case complete. | |
| 03/14/2014 | Record returned from Supreme Court. | |
| 05/19/2014 | Shipped to state retention center, box # / list #: | L345 |
| 01/21/2016 | Shipped to state retention center, box # / list #: | L359 |
Briefs
Asahi Kasei Pharma Corporation v. Actelion Ltd. et al.
Division 5
Division 5
Case Number A133927
| Brief | Due Date | Date Filed | Party and Attorney | Notes |
|---|---|---|---|---|
| Appellant's opening brief. | 07/23/2012 | Defendant and Appellant: Jean-Paul Clozel Attorney: Susan Heikkinen Handelman Defendant and Appellant: Martine Clozel Defendant and Appellant: Simon Buckingham | | |
| Appellant's opening brief. | 07/24/2012 | Defendant and Appellant: Actelion Ltd. Attorney: Donald Manwell Falk Defendant and Appellant: Actelion Pharmaceuticals Ltd. Defendant and Appellant: Actelion Pharmaceuticals US Inc. Defendant and Appellant: Actelion US Holding Company | 07/23/2012 REDACTED AND UNREDACTED versions per order filed on 8/15/12 | |
| Respondent notified re failure to file respondent's brief. | 11/19/2012 | Plaintiff and Appellant: Asahi Kasei Pharma Corporation Attorney: Christopher John Banks | | |
| Respondent's brief. | 01/11/2013 | Plaintiff and Appellant: Asahi Kasei Pharma Corporation Attorney: Christopher John Banks | 11/13/2012 ***Redacted and unredacted versions; see order filed on 12/26/12*** 2 CDs containing the redacted and unredacted briefs | |
| Appellant's reply brief. | 04/05/2013 | Defendant and Appellant: Actelion Ltd. Attorney: Donald Manwell Falk | 03/13/2013 ***redacted and unrdacted versions**** | |
| Appellant's reply brief. | 04/05/2013 | Defendant and Appellant: Jean-Paul Clozel Attorney: Susan Heikkinen Handelman | 03/13/2013 1 volume of public version of appendix 1 volume of SEALED appendix 2 CDs containing the public and SEALED versions of appendix (in gray envelope) | |
| Appellant's reply brief. | 05/03/2013 | Plaintiff and Appellant: Asahi Kasei Pharma Corporation Attorney: Christopher John Banks | X-ARB filed per AR 8.25(b)(3) |
Future Scheduled Actions
Asahi Kasei Pharma Corporation v. Actelion Ltd. et al.
Division 5
Division 5
Case Number A133927
No information found.
Disposition
Asahi Kasei Pharma Corporation v. Actelion Ltd. et al.
Division 5
Division 5
Case Number A133927
Description:
Affirmed in full
Date:
12/18/2013
Disposition Type:
Final
The judgments are affirmed. Asahi shall recover its costs on appeal.
The judgments are affirmed. Asahi shall recover its costs on appeal.
Publication Status:
Signed Partial Published
Author:
Bruiniers, Terence L.
Participants:
Jones, Barbara J. R. (Concur)
Needham, Jr., Henry E. (Concur)
Needham, Jr., Henry E. (Concur)
Case Citation:
222 Cal.App.4th 280, 222 Cal.App.4th 945
Trial Court
Asahi Kasei Pharma Corporation v. Actelion Ltd. et al.
Division 5
Division 5
Case Number A133927
Trial Court Name:
San Mateo County Superior Court - Main (Redwood City)
County:
San Mateo
Trial Court Case Number:
CIV478533
Trial Court Judge:
Weiner, Marie
Trial Court Judgment Date:
11/21/2011